| 10.03.22 | AstraZeneca pays hefty markup to buy LogicBio; Clene stock craters after ALS flop

Klicken Sie hier, um Fiercebiotech.com zu abonnieren

Laden...

2 jahre vor

Html
Text

Webinar: Cells to purified capsids: How to develop a scalable rAAV process

Tuesday, October 11, 2022 | 10am ET / 7am PT

Join us to learn about common pitfalls for rAAV processing and ways to overcome the challenges. Key for a successful process are high viral genome productivity and full capsids in the harvest material, with high overall yield and efficient impurity removal. Register now.

Today's Big News

Oct 3, 2022

Spying a devilish deal, AstraZeneca pays 666% premium to buy genomic medicine biotech

Clene break: Biotech’s shares slump 30% on ALS phase 2 flop

Incyte scoops up preclinical biotech to widen footprint in vitiligo

SPAC on track: Preclinical T-cell company Estrella latest in string of biotechs to take blank check route

After $100M deal, J&J links gene therapy to improved vision in early-phase trial

Mesoblast keeps hopes of cell therapy approval alive in latest response to FDA

Fierce Biotech Summit: Gene editing execs reflect on promises and challenges as CRISPR celebrates 10-year anniversary

Scandion posts phase 2 trial flop just one month after the departure of 2 top execs

Don't junk DNA as study shows new role in brain disease


A message from GemPharmatech

Featured

Spying a devilish deal, AstraZeneca pays 666% premium to buy genomic medicine biotech

By Nick Paul Taylor

AstraZeneca has identified a shortcut to prominence in the genomic medicine space. Working through its Alexion rare disease unit, the Big Pharma has struck a deal to snap up struggling LogicBio Therapeutics to secure technology platforms and expertise in their use.

Not so Clene break: Biotech’s shares slump 34% on phase 2 ALS flop despite plans to continue testing

By James Waldron

Clene Nanomedicine came up short in a phase 2 trial of its only clinical-stage asset in amyotrophic lateral sclerosis but is nonetheless laying a path forward for the drug in ALS. As a result, the biotech’s shares plummeted 34% from $2.80 apiece on Friday to $1.83 as the markets opened Monday.

Incyte scoops up preclinical biotech to widen footprint in vitiligo

By Max Bayer

Incyte is scooping up a preclinical biotech to potentially expand its vitiligo treatment footprint. The company is shelling out $70 million upfront to buy Villaris Therapeutics, with more than $1.36 billion available in biobucks.

SPAC on track: Preclinical T-cell company Estrella latest in string of biotechs to take blank check route

By Gabrielle Masson

A string of recent biotech SPAC mergers in biotech could put the so-called blank check deals back on track after near-extinction. The latest is early-stage cancer therapeutics company Estrella Biopharma, which signed a deal to merge with TradeUP Acquisition. Corp.


A message from Fierce Biotech and Fierce Pharma

After $100M deal, J&J links gene therapy to improved vision in early-phase trial

By Nick Paul Taylor

Johnson & Johnson has posted clinical data on its $100 million gene therapy bet. The Big Pharma linked its inherited retinal disease candidate to improved vision in a phase 1/2 clinical trial, offering insights into how it may perform in an ongoing pivotal study.

Mesoblast keeps hopes of cell therapy approval alive in latest response to FDA

By James Waldron

Mesoblast isn’t giving up on its allogeneic cell therapy remestemcel-L. The FDA knocked back the biotech in September 2020, issuing a complete response letter to Mesoblast’s approval request for its mesenchymal stromal cell therapy in children with steroid-resistant graft-versus-host disease.

Fierce Biotech Summit: Gene editing execs reflect on promises and challenges as CRISPR celebrates 10-year anniversary

By Angus Liu

The first wave of gene-editing-based therapies are coming to fruition. At the recent Fierce BIotech Summit, executives from Beam, Intellia, Novartis and Tessera highlighted progresses in the burgeoning field in the past ten years as well as challenges before gene editing could reach more patients.

Scandion posts phase 2 trial flop just one month after the departure of 2 top execs

By Max Bayer

Just a month after two top executives announced their departure, Scandion posted a phase 2 flop of its sole asset. The company says SCO-101 failed to produce a high enough tumor reduction rate to pass the trial's primary endpoint.

Don't junk DNA as study shows new role in brain disease

By Helen Floersh

Researchers at the University of Sheffield have discovered that junk DNA, or non-coding DNA, can break—and if it isn’t repaired, can contribute to the development of neurodegenerative disease. They hope their findings will lead to the identification of disease biomarkers along with new therapies.

Tasso's at-home blood sample collectors to arm Catapult's virtual checkups

By Conor Hale

Catapult will propel the Tasso+ blood collector into people's homes as part of its VirtualCheckup program.

Otsuka's Taiho Oncology bags approval for bile duct cancer med Lytgobi, teeing up showdown with BridgeBio and Incyte

By Fraiser Kansteiner

Late last week, Otsuka’s Taiho Oncology and Taiho Pharmaceutical nabbed accelerated approval for their drug futibatinib in adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma in the liver with fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.

Even 'relatively weak' hurricane could sideline hundreds of coastal hospitals, study warns

By Dave Muoio

A new analysis estimates 25 coastal metros would see the majority of their hospitals hamstrung by a Category 2 hurricane or stronger. The number is only expected to increase as climate change raises sea levels.

MIT team develops burrowing robotic pill to break through the intestine's drug-blocking mucus

By Conor Hale

Researchers at the university have developed a motorized pill with a spinning, augerlike end piece designed to displace the mucus and deliver its payload directly to the organ.

Fierce podcasts

Don't miss an episode

'The Top Line': What makes the Fierce 15 honorees tick, Fierce Biotech Summit's spotlight on gene editing and the bear market

This week on "The Top Line," we talk with many of the Fierce 15 honorees to find out what makes them unique. We also share highlights from the Fierce Biotech Summit on gene editing innovations and battling biotech's bear market.

'Podnosis': Broadening artificial intelligence's scope in healthcare, how payers can invest in social needs


A message from Fierce Pharma

Resources

eBook

Optimize the value and impact of your real-world data

With real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy.

Navigating the Data Deluge: Turning Data Into Insight Across the Health Care and Life Sciences Industries

Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem.

A Guide to Pre-Validated Software-as-a-Service LIMS

SaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security.

Cutting Through the Noise: Crossing the New Real World Data Landscape

Read about key factors and trends in RWE and how our data luminaries are the right partner to lead the way forward.

Commercializing Gene Therapies, Part I - Introduction

This paper is the first in a 4-part series focused on developing commercial models for gene therapies

Sponsored by: Blue Matter, strategic consultants in the life sciences

eBook

Make the most out of hybrid conferences

Improve your congress competitive intelligence and cut down costs by 50%

Sponsored by: Ferma.AI, a Product of ZoomRx

eBook

Optimize Digital Engagement Across the Patient Journey

Improve patient engagement, adherence, and outcomes

Achieving faster formulation for First In Human supplies

Supporting your product development programme through experience, expertise, and efficiency.

Building a Broader Tissue Research Ecosystem

Learn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue.

Improve Life Sciences Research with AI Workflow Automation

Can an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster?

The Most Suitable Dosage Form Technologies for the Oral Delivery of Lipid-Based Formulations

What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?

Sponsored by: Catalent

Research

Versatility of Softgel Technology - Encapsulation of a Volatile Compound

Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound.

Sponsored by: Catalent

Whitepaper

Lipid-Based Drug Delivery System to Bring Poorly Soluble Drugs to Market

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?

Sponsored by: Catalent

Whitepaper

Formulation Strategies When Transitioning From Vial to PFS

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

The Faster Path From Pre-Filled Syringe to Auto-Injector

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.

Scaling life sciences companies: Discover resources to support growth and innovation

Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals.

Softgel Formulation Enables Oral Delivery of Testosterone

Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy.

Sponsored by: Catalent

Whitepaper